Robert W Simms, MD

Clinical Core PIRob

Dr. Simms Rheumatology Section Chief at Boston University School of Medicine.  His major research interest is in scleroderma clinical outcome measures and clinical trials.  He is the most active scleroderma clinician in the section, and is the site PI on multiple past and ongoing multicenter trials.  He partners with Dr. Lafyatis in clinical and translational studies.  This has included a recently completed trial of rituximab in systemic sclerosis.  He works very closely with Dr. Farber on clinical issues as well as clinical trial initiatives in pulmonary hypertension.  Dr. Simms receives NIH support as the site PI on a multi-center trial of high dose immunosuppressive therapy and autologous bone marrow transplant compared to cyclophosphamide (SCOT).

Institution: Boston University School of Medicine

Academic Rank: Professor of Medicine

Medical school/Degree/Year: University of Rochester School of Medicine/MD/1980

Mailing address: 72 East Concord Street, E-5, Boston, MA 02118

Email: rsimms@bu.edu

Phone: 617.638.4310

Summary of academic interest: Clinical and translational studies of scleroderma spectrum disorders

CORT Project summary:  Clinical Core PI

Recent publications relevant to the CORT:

Kissin EY, Schiller AM, Gelbard RB, Anderson JJ, Falanga V, Simms RW, Korn JH, Merkel PA. Durometry for the assessment of skin disease in systemic sclerosis. Arthritis Rheum. 2006 Aug 15;55(4):603-9.PMID: 16874783.

Clements PJ, Roth MD, Elashoff R, Tashkin DP, Goldin J, Silver RM, Sterz M, Seibold JR, Schraufnagel D, Simms RW, Bolster M, Wise RA, Steen V, Mayes MD, Connelly K, Metersky M, Furst DE; Scleroderma Lung Study Group. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis. 2007 Dec;66(12):1641-7. Epub 2007 May 7.PMID: 17485423.

Khanna D, Lovell DJ, Giannini E, Clements PJ, Merkel PA, Seibold JR, Matucci-Cerinic M, Denton CP, Mayes MD, Steen VD, Varga J, Furst DE; Scleroderma Clinical Trials Consortium co-authors. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis. 2008 May;67(5):703-9. Epub 2007 Sep 24.PMID: 17893248.

Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009 Feb;60(2):578-83.PMID: 19180481.

Radstake TR, van Bon L, Broen J, Hussiani A, Hesselstrand R, Wuttge DM, Deng Y, Simms RW, Lubberts E, Lafyatis R. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One 2009;4(6):e5903.

BU_SclerodermaLogoFnl_SMALL